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Sepsis is a serious medical condition characterized by a systemic inflammatory response 
syndrome (SIRS) due to infection. The incidence of sepsis in intensive care in NZ is 
11.8%, has a mortality rate of 37.5%, and costs NZ$100M per year. Guidelines 
recommend early intervention within 6 hours. However, blood culture test confirmation 
may take up to 48 hours, by which time the disease may be advanced, and only 51% of 
sepsis cases have a positive culture. Thus, due to delayed and often inconclusive data, 
physicians often pre-emptively prescribe broad-based antibiotic therapy, increasing 
antibiotic resistance and costs. In contrast, failure to prescribe antibiotics early can lead 
to increased sepsis mortality. Hence, there is a significant need for a timely, accurate 
and non-invasive sepsis diagnostic test to support clinical treatment decisions. 
 
Insulin sensitivity is decreases with worsening patient condition. A validated model-
based glycemic control protocol can estimate insulin sensitivity hourly or more 
frequently in “clinical real time”. The primary research hypothesis is that model-based 
insulin sensitivity and physiological characteristics can be used to diagnose sepsis and 
assess its severity in real-time, thus providing the earliest possible detection.  
 
A clinical biomarker for sepsis was calculated from real-time, model-based insulin 
sensitivity glycemic control data and physiological data, including: temperature, heart 
rate, respiratory rate, blood pressure, SIRS score, and their respective hourly rates of 
change from 36 patients with sepsis. Patients were identified as having sepsis based on a 
clinically validated sepsis score (ss) of 2 or higher (ss = 0-4 for increasing severity). 
Kernel density estimates are used development of joint probability density profiles for 
these data and for classification. The stratified bootstrap method and in-sample 
estimates were used to estimate bounds for prediction error of the classification model 
created. Area under the receiver operator characteristic (ROC) curve (AUC) was 
calculated to evaluate the discriminative ability of the test across a full range of cutoff 
values.  From the ROC, the optimal probability cutoff value for classification was 
determined 
 
The clinical biomarker for sepsis diagnosis at an optimal probability cutoff value of 
0.319 has 94.4% sensitivity, 94.4% specificity for in-sample error. The ROC AUC is 
0.989 for in-sample data. Thus, the clinical biomarker provides an effective real-time 
negative predictive diagnostic for sepsis with high accuracy. Negative prediction 
enables clinicians to negate pre-emptive antibiotic prescription. These statistical 
methods will be used to analyse the diagnostic properties of a refined clinical biomarker 
to be developed from the ongoing prospective clinical trial at Christchurch Hospital.  
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